Background: The proposed revision of the ICD-10 category of ‘acute and transient psychotic disorders' (ATPDs), subsuming polymorphic, schizophrenic or predominantly delusional syndromes, would restrict their classification to acute polymorphic psychotic disorder, reminiscent of the clinical concepts of bouffée délirante and cycloid psychosis. Sampling and Methods: We selected all subjects aged 15-64 years (n = 5,426) who were listed in the Danish Psychiatric Central Register with a first-admission diagnosis of ATPDs in 1995-2008 and estimated incidence rates, course and outcome up to 2010. Results: Although about half of ATPD patients tended to experience transition to another category over a mean follow-up period of 9.3 years, acute polymorphic psychotic disorder fared better in terms of cases with a single episode of psychosis and temporal stability than the subtypes featuring schizophrenic or predominantly delusional symptoms. Acute polymorphic psychotic disorder was more common in females, while cases with acute schizophrenic features predominated in younger males and evolved more often into schizophrenia and related disorders. Conclusions: These findings suggest that acute polymorphic psychotic disorder exhibits distinctive features and challenge the current approach to the classification of ATPDs.

Keywords:
Acute transient psychotic disorders, Bouffée délirante, Brief psychotic disorder, Cycloid psychosis, ICD-10
1.
Kraepelin E: Psychiatrie. Leipzig, Barth, 1896.
2.
Castagnini A, Berrios GE: Acute transient psychoses and their differentiation from schizophrenia. Cur Psychiatry Rev 2011;7:248-255.
3.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992.
4.
Weibel H, Metzger JY: Psychoses délirantes aiguës. EMC Psychiatrie 2005;21:40-61.
5.
Kleist K: Über zykloide und epileptoide Psychosen und über die Frage der Degenerationspsychosen. Schweiz Arch Neurol Psychiatr 1928;23:3-37.
6.
Leonhard K: Aufteilung der endogenen Psychosen. Jena, Akademie, 1975.
7.
Nugent KL, Paksarian D, Mojtabai R: Nonaffective acute remitting psychoses: uncertainties on the way to DSM-V and ICD-11. Cur Psychiatry Rep 2011;13:203-210.
8.
Singh SP, Burns T, Amin S, Jones PB, Harrison G: Acute and transient psychotic disorders: precursors, epidemiology, course and outcome. Br J Psychiatry 2004;185:452-459.
9.
Pillmann F, Marneros A: Longitudinal follow-up in acute and transient psychotic disorders and schizophrenia. Br J Psychiatry 2005;187:286-287.
10.
Aadamsoo K, Saluveer E, Küünarpuu H, Vasar V, Maron E: Diagnostic stability over 2 years in patients with acute and transient psychotic disorders. Nord J Psychiatry 2011;65:381-388.
11.
Castagnini A, Foldager L, Bertelsen A: Long-term stability of acute and transient psychotic disorders. Aust NZ J Psychiatry 2013;47:59-64.
12.
Castagnini A, Foldager L: Variations in incidence and age of onset of acute and transient psychotic disorders. Soc Psychiatry Psychiatr Epidemiol 2013;48:1917-1922.
13.
Rusaka M, Rancāns E: First-episode acute and transient psychotic disorder in Latvia: a 6-year follow-up study. Nord J Psychiatry 2014;68:24-29.
14.
Gaebel W: Status of psychotic disorders in ICD-11. Schizophr Bull 2012;38:895-898.
15.
Mors O, Perto GP, Mortensen PB: The Danish Psychiatric Central Research Register. Scand J Public Health 2011;39(suppl 7):54-57.
16.
Castagnini AC, Laursen TM, Mortensen PB, Bertelsen A: Family psychiatric morbidity of acute and transient psychotic disorders and their relationship to schizophrenia and bipolar disorder. Psychol Med 2013;43:2369-2375.
17.
Sajith SG, Chandrasekaran R, Sadanandan Unni KE, Sahai A: Acute polymorphic psychotic disorder: diagnostic stability over 3 years. Acta Psychiatr Scand 2002;105:104-109.
18.
Linden SC, Harris M, Whitaker C, Healy D: Religion and psychosis: the effect of the Welsh religious revival in 1904-1905. Psychol Med 2009;40:1317-1323.
19.
Salvatore P, Baldessarini RJ, Tohen M, et al: McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry 2011;72:183-193.
20.
Das SK, Malhotra S, Basu D, Malhotra R: Testing the stress-vulnerability hypothesis in ICD-10-diagnosed acute and transient psychotic disorders. Acta Psychiatr Scand 2001;104:56-58.
21.
Susser E, Wanderling J: Epidemiology of nonaffective acute remitting psychosis versus schizophrenia. Sex and sociocultural setting. Arch Gen Psychiatry 2004;51:294-301.
22.
Mojtabai R, Varma VK, Susser E: Duration of remitting psychoses with acute onset: implications for ICD-10. Br J Psychiatry 2000;176:576-580.
23.
Castagnini A, Bertelsen A: Mortality and causes of deaths of acute and transient psychotic disorders. Soc Psychiatry Psychiatr Epidemiol 2011;46:1013-1017.
24.
Castagnini A, Foldager L, Bertelsen A: Excess mortality of acute and transient psychotic disorders comparison with bipolar affective disorder and schizophrenia. Acta Psychiatr Scand 2013;128:370-375.
25.
Castagnini AC: Wimmer's concept of psychogenic psychosis revised. Hist Psychiatry 2010;21:54-66.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.